From there a long slow steady march towards $100/share and with the recent involvement of Goldman and JPM in addition to Visium, the votes of confidence are all in place. The analyst must really like the story forming here. Sure you will get bobs etc in the price but it is time to forget the noise and ride long term wit MNTA, sorry shorts I know that isn't the short term thing you wish to project but it's there and forming Necuparinib and Humira Biosim not wishstanding
i concur. actually see this at $30 with US Supreme Court announcement and launch before September with Glatopa. Once it hits $30, we will be at or near $40 by September. Momentum has changed. Company now seen through optimistic and positive lens. They have fought, persevered and now will be rewarded financially and with an increasing stock price. It's a steal at under $25 before US Supreme Court announcement which could come any day. Plus, FDA already giving favor and preference to MNTA. Great things in store— (1 Samuel 2:7).
I think the story is starting to resonate with the leading analyst and book runners/deal runners. Momenta is poised for a break out year and 2016 is looking tantilizing for the big players involved. I know Jacob Gottlieb loaded the boat before the placement and I am sure he took part in that round too. He was closing in on 4 million shares, that is all recent and a true vote for the future. This guy doesn't miss in this space!! I am in big and loaded the wife with a couple thousand shares a few weeks ago. I am still buying today in my accounts.
great! $30 would get me the hood and the tires... my factory ordered McLaren 650 Spider is taking shape.... varroooM!... k
Happens! Then is or a bit lower could happen a whole lot sooner. I see a combo with this company as it's propellant and booster to the aquirer to launch it much higher, like a quick $10-12 and that is a screaming deal!!!!!!!!!!!!!!! The merging company would get a plethora of awesome future developments, Biosimilar and Proprietary, Necuparinib who I told my good friend that just got diagnosed to become a test subject! This cancer kills fast, the results looks promising and the side effects less than a hangover, get it done Momenta!!!
CALPERS... according to a recent article in the Wall Street Journal, the California Public Employees' Retirement System will cut in half those that manage their money. This 'huge move' will mean that the managers that performed well and made money for them will receive more money to invest, while those that didn't will get axed.
This new mantra bodes well for Momenta... Recent filing shows Calpers has taken and increased its stake in this stock... with a surging stock price we are one of their profitable positons... and with Calpers new stance, new money will flow in our way... moo k
Now stands at 8.4 mill. as of 5/29/15. Thought more would cover based on September launch of Glatopa, view this as a little positive when launch happens.
The CEO said he would sign all day long partnerships for 50/50 split , No one seams to be presenting those to him. More than likely appellate court wont hand them any victory before Sept 1 patent expiration date, courts just take a long time. Small amount of cold water there. Enoxoparin appeal seams pie in the sky. Most phase 1 trials (Necuparanib) allways looks good for dosing and adverse reactions-wait for phase 3 results to either laugh or cry. Warmer water would be; 2 platforms every year in 5 years, with their science should produce very 10 promising candidates .Recent offering gives them cash to advance a few things.
they are setting up the partnership papers to sign as we speak.. We will have an appellate decision within two weeks.... We will have our day in the courts with Amphastar.. True about Phase 1 drugs but by the time phase 3 comes around MNTA will be a 300 lbs. gorilla and growing to a 450 lbs. silverback onto 800 lbs. if it is successful in the courts and its own novel drugs... thses events will dictate if I will be either laughing in my midnight blue Carrera or crying in my McLaren 650S... ... moo k
overall it increased about 1.5 million since they announced the FDA approval...
pre-approval - April 15,2015... 6,785,503
approval April 16,2015 ...
post approval- May 29,2015... 8,404,121
a hui hou... k
but the next reporting period post approval which is April 30, the short interest is 7,929,601... which means the shorts piled on within 15 days of post approval a total of 1,144,098 shares... these shares are underwater at the MOMENT(a).... I also think, since there is no SEC filings showing any increases in the 5% and above owners, it means to me that the book runners, GS and JP Morgan could be the major shorts... and they are using the newly minted shares as shield(insurance).to their short position.. moo k
Love your info. Help me with this. Why would any company sell 8 million shares to a bank without a stipulation the shares not be sold short.
jgs3rd, why would a company put such a stipulation? Think of the nightmare in tracking those shares once it is sold by the bank... and, if I were a bank and bought 8 million shares, I'd be psissed if I can't do anything I please with my shares, including lending it to out to anyone who will sell it short... moo k